Cryoablation versus thoracoscopic surgery for ground-glass lung nodules

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, non-randomized study enrolling about 160 adults with pulmonary ground-glass nodules (8–20 mm, ≤25% solid component) who are candidates for either procedure. Participants choose between image-guided percutaneous cryoablation or video-assisted thoracoscopic surgery (VATS) and are followed for outcomes including 2-year disease-free survival, overall survival, local recurrence, procedure completion rates, and safety. The primary endpoint is 2-year disease-free survival, and secondary endpoints include 1-month mortality, 5-year disease-free survival, local recurrence, completion rates, and complications. Patients receive multidisciplinary evaluation and are treated and followed at Shanghai Chest Hospital.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients ≥ 18 years old.
2. The size of the GGN is 8-20mm (with less than 25% solid component), and the number of nodules requiring treatment in the short term is less than 3.
3. Pathological confirmation of the GGN as non-small cell lung cancer; or progression of the GGN during at least 3 months of follow-up, including enlargement of the largest diameter, increase in solid component, or the appearance of a significant solid component in a previously pure GGN, with multidisciplinary discussion (including radiology, thoracic surgery, and pulmonology) suggesting malignancy.
4. No lymph node, pulmonary, or distant metastasis to other organs.
5. After multidisciplinary evaluation, the patient is considered capable of tolerating both surgical and ablation procedures.
6. Unsuitable for radiation therapy or refusal of radiation therapy.
7. Willing to participate in this clinical study and sign the informed consent form.

Exclusion Criteria:

1. Patients in poor general condition, with ECOG physical fitness score \>2, unable to tolerate surgery or ablation therapy, or with relevant contraindications.
2. Patients who have previously received other treatments for pulmonary GGNs.
3. Patients with poor compliance.
4. Severe heart, lung, kidney, brain, or other vital organ diseases.
5. Active bacterial or fungal infections.
6. Simultaneous or metachronous (within the past 5 years) double cancers.
7. Women during pregnancy or breast-feeding.
8. History of radiation therapy.
9. Bleeding tendency, abnormal coagulation functions, or coagulation disorders that cannot be corrected after treatment.
10. Contraindications to general anesthesia.
11. Expected survival time \< 6 months.
12. The researcher believes that it is not suitable for inclusion.

Where it's running

• Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Jiayuan Sun, MD, PhD
• Email: xkyyjysun@163.com
• Phone: +86-021-22200000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sacituzumab Govitecan plus Tislelizumab for advanced esophageal cancer

  This phase II study tests whether the cancer-fighting drug sacituzumab tirumotecan (SKB264) combined with tislelizumab can help adults with advanced esophageal squamous cell carcinoma that progressed after initial immunotherapy.

  Recruiting at 2 sites Phase 2 Shanghai Chest Hospital · Shanghai and 1 other locations · NCT07811752

• Femtosecond laser imaging with FastLung AI for intraoperative lung diagnosis

  This study tests whether labeling-free femtosecond laser imaging with FastLung AI can match the accuracy of standard frozen sections for diagnosing lung tumors during surgery.

  Recruiting at 4 sites Shanghai Chest Hospital · Shanghai, Shanghai Municipality and 4 other locations · NCT07681245

• Pre-Emptive Parecoxib for Pain During CT-Guided Lung Nodule Localization

  This study tests whether giving parecoxib sodium before a CT-guided needle localization of lung nodules can reduce pain for patients undergoing VATS.

  Recruiting Phase 4 Shanghai Chest Hospital · Shanghai, Shanghai Municipality · NCT07675473

• Induction chemoimmunotherapy plus chemoradiotherapy and consolidation immunotherapy in unresectable locally advanced NSCLC

  This trial tests induction chemoimmunotherapy followed by chemoradiotherapy and consolidation immunotherapy in adults with unresectable stage III NSCLC to see if it can improve outcomes compared with the standard PACIFIC approach.

  Recruiting Phase 1/2 Shanghai Chest Hospital · Shanghai, Xuhui · NCT07632365

• Prospective cohort of SCLC patients receiving radiotherapy-based comprehensive treatment

  This project will collect detailed clinical, imaging, pathology, and molecular data from adults with limited-stage SCLC who receive radiotherapy with or without chemotherapy and immunotherapy to try to identify which radiotherapy timing, dose, and combinations work best.

  Recruiting Shanghai Chest Hospital · Shanghai, Shanghai Municipality · NCT07565532

• Septum-guided segmentectomy for deep early-stage lung cancer

  This trial tests a precise septum-guided, lung-sparing surgery to remove small, deep early-stage non-small cell lung cancers in adults while preserving more healthy lung tissue.

  Recruiting Shanghai Chest Hospital · Shanghai, Shanghai Municipality · NCT07564557

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.